We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sandoz Group Ag | LSE:0SAN | London | Ordinary Share | CH1243598427 | SANDOZ GROUP ORD SHS |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | USD 9.65B | USD 77M | USD - | - |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
17:34:55 | O | 21 | 37.9686 | CHF |
Date | Time | Source | Headline |
---|---|---|---|
12/8/2024 | 06:00 | UKREG | Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further.. |
08/8/2024 | 06:00 | UKREG | Sandoz reports second-quarter sales and half-year 2024 results |
25/7/2024 | 06:00 | UKREG | Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat.. |
01/7/2024 | 06:00 | UKREG | FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized.. |
22/5/2024 | 06:00 | UKREG | Sandoz receives European Commission approval for Wyost® and Jubbonti®, the.. |
07/5/2024 | 06:00 | UKREG | Sandoz reports first quarter 2024 sales |
30/4/2024 | 11:25 | UKREG | Shareholders approve all resolutions proposed by Board of Directors at.. |
30/4/2024 | 06:00 | UKREG | Sandoz reaches agreement with Amgen resolving all patent litigation related.. |
22/4/2024 | 06:00 | UKREG | Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab),.. |
21/3/2024 | 13:00 | UKREG | Sandoz opens new antibiotic production facility in Austria, to.. |
Sandoz (0SAN) Share Charts1 Year Sandoz Chart |
|
1 Month Sandoz Chart |
Intraday Sandoz Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions